Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Deals Of The Week Ponders When $2.1 Billion Is A Steal

Executive Summary

M&A can be expensive, but sometimes deals pay huge dividends. Bristol’s $2.1 billion acquisition of Medarex from 2009 looks like it’ll pay for itself many times over. Plus Actavis buys Warner Chilcott, Novo buys Xellia, and Elan and BTG each keep very busy.


Related Content

MorphoSys: Accelerating The Long Transformation
Antibiotic Commercial Models Under Revision To Tackle Stewardship Tension
BTG Makes Two Buys To Build Interventional Medicine Business
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
Norway’s Xellia Pharma Acquired By Novo A/S In $700 Million Buyout
Elan Makes A $1 Billion Theravance Royalty Play; What Will Investors Say?
Investors Crow For Shares Of Zoetis As It Begins Trading On The NYSE
Antibiotic Market Snapshot: In Exchange For Higher Prices, More Value
What Medarex Has To Offer At $2.4 Billion
Lilly Snatches ImClone Away From Bristol


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts